News Releases
View all Historical Press Releases
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
Su | Mo | Tu | We | Th | Fr | Sa |
---|---|---|---|---|---|---|
-
Dec 21, 2016
Educating your customers and prospects by sharing expertise and insight is at the heart of content marketing. According to a recent article by Joe Pulizzi, "Lethal Generosity: The Key to Your...
-
Dec 21, 2016
Educating your customers and prospects by sharing expertise and insight is at the heart of content marketing. According to a recent article by Joe Pulizzi, "Lethal Generosity: The Key to Your...
-
Dec 21, 2016
Educating your customers and prospects by sharing expertise and insight is at the heart of content marketing. According to a recent article by Joe Pulizzi, "Lethal Generosity: The Key to Your...
-
Dec 20, 2016Supported with NIAID Contract Funding of up to $24.7 million
Princeton, NJ – December 20, 2016 – Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to...
-
Dec 16, 2016
Princeton, NJ, December 16, 2016 – Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is...
-
Dec 13, 2016
Princeton, NJ, December 13, 2016 – Soligenix, Inc. (Nasdaq: SNGX), a late-stage biopharmaceutical company focused on developing and commercializing products to treat rare diseases where there is...
-
Dec 12, 2016
Princeton, NJ – December 12, 2016 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Dec 8, 2016Friday, December 16, 2016, from 8:30-9:30 am ET
Princeton, NJ – December 8, 2016 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Dec 8, 2016Study data supports advancing development to pivotal Phase 2b/3 program
Princeton, NJ – December 8, 2016 – Soligenix, Inc. (OTCQB: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...
-
Nov 10, 2016Highlighted by Revenues of $3.0 Million
Princeton, NJ – November 10, 2016 – Soligenix, Inc. (OTCQB: SNGX (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to treat...